Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib versus gemcitabine + cisplatin as first-line treatment for FGFR2-rearranged advanced intrahepatic cholangiocarcinoma
NL-OMON52381Phase 3Not yet recruiting
- Sponsor
- Taiho Oncology
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of futibatinib in cholangiocarcinoma (CCA) and intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Taiho Oncology. Primary endpoint: Progression-free survival per independent central review. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
futibatinib
03
Conditions
cholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NL-OMON52381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52381.